In this study sixty subjects will be treated with high dose statins for 8 weeks followed by 8 weeks of high dose statin + evolocumab (420mg/4 wk) therapy. The laboratory assessments will be performed at the screening (baseline), after 8 weeks of high-dose statin therapy, and 24 hr and 8 weeks after high dose statin + evolocumab therapy